Sort   by:  
 Page size 
UnknownLater cART initiation in migrant men from sub-Saharan Africa without advanced HIV disease in France.
Not available
S-EPMC4348541 | biostudies-literature
UnknownResearch engagement and patient-reported quality of care: a cross-sectional study of UK inflammatory bowel disease services.
Not available
S-EPMC12853465 | biostudies-literature
UnknownDurability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice.
Not available
S-EPMC4695083 | biostudies-literature
UnknownAntibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Not available
S-EPMC8927425 | biostudies-literature
UnknownNeutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903 | biostudies-literature
UnknownComparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.
Not available
S-EPMC4643831 | biostudies-literature
UnknownBoosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
Not available
S-EPMC4447777 | biostudies-literature
Sort   by:  
 Page size